TIMELESS诱导鼻咽癌放疗抵抗的分子机制
批准号:
81772877
项目类别:
面上项目
资助金额:
52.0 万元
负责人:
郭灵
依托单位:
学科分类:
肿瘤治疗抵抗
结题年份:
2021
批准年份:
2017
项目状态:
已结题
项目参与者:
林晓平、刘赛兰、王琳、朱茜、文雯、金亚南
中文摘要
目前放射治疗是鼻咽癌的首选治疗方式,放疗抵抗是导致鼻咽癌治愈率大大降低的最主要原因。相关研究发现NF-κB是导致肿瘤细胞辐射抵抗的关键因素。近期我们的研究发现TBLR1激活NF-kB信号通路抑制鼻咽癌细胞的凋亡,降低鼻咽癌细胞对放化疗的敏感性(通讯作者 Molecular cancer IF=5.397)。在深入研究NF-kB信号通路影响鼻咽癌放疗敏感性的机制时我们发现TIMELESS可激活NF-κB信号通路进而影响鼻咽癌放疗敏感性,然而其详细分子机制有待阐明。本项目采用细胞、分子生物学及动物实验探讨TIMELESS激活NF-κB信号通路,促进抗凋亡作用诱导鼻咽癌细胞发生放射抵抗的详细分子机制;并从临床标本中验证TIMELESS与NF-κB通路的关系,深层次解析TIMELESS促进鼻咽癌放疗抵抗的分子机制,为早期预测鼻咽癌放疗抵抗提供新的理论依据,为治疗提供新的靶点。
英文摘要
At present, radiotherapy is the main treatment for nasopharyngeal carcinoma (NPC) . Radio-resistance is the main reason leading to greatly reduced cure rate of NPC. Studies found that NF-κB is a key factor in the radio-resistance of tumor cells. Recently, our study found that TBLR1 activates NF-kB signaling pathway to inhibit the apoptosis and reduce the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy (Correspondent Molecular cancer IF = 5.397). In the study of the mechanism of NF-κB signaling pathway affecting the radio-sensitivity of nasopharyngeal carcinoma, we found that TIMELESS can activate NF-κB signaling pathway to affect the radio-sensitivity of nasopharyngeal carcinoma, but its detailed molecular mechanism needs to be clarified. In this project, the molecular mechanism of TIMELESS activation of NF-κB signaling pathway and the promotion of anti-apoptosis to induce the radio-resistance of nasopharyngeal carcinoma cells were studied by cell, molecular biology and animal experiments. The relationship of TIMELESS and NF-κB pathway will be confirmed from clinical specimens to further explore the molecular mechanism of TIMELESS to promote the radio-resistance of nasopharyngeal carcinoma. This will provide a new theoretical basis for early prediction of radio-resistance and providing a new target for treatment of nasopharyngeal carcinoma.
目前放射治疗是鼻咽癌的首选治疗方式,放疗抵抗是导致鼻咽癌治愈率大大降低的最主要原因。本研究旨在探讨TIMELESS促进鼻咽癌放疗抵抗的分子机制。本课题组发现TIMELESS基因在鼻咽癌细胞及组织中高表达,高表达TIMELESS与鼻咽癌不良预后显著相关。进一步分子机制研究结果表明,高表达TIMELESS可激活NF-κB信号通路并可增强鼻咽癌干细胞特性及促进放射治疗后的 DNA 损伤修复导致放射治疗抵抗。本研究成果表明:TIMELESS促进鼻咽癌放疗抵抗中发挥重要作用,为早期预测鼻咽癌放疗抵抗提供新的理论依据,为治疗提供新的靶点。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
登录
查看更多内容
Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.
建立肌肉减少症模型来预测接受同步放化疗的鼻咽癌患者的生存期。
DOI:
10.3389/fonc.2021.625534
发表时间:
2021
期刊:
Frontiers in oncology
影响因子:
4.7
作者:
[Hua X, Li WZ, Huang X, Wen W, Huang HY, Long ZQ, Lin HX, Yuan ZY, Guo L]
通讯作者:
Guo L
The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma.
RARS-MAD1L1 融合基因诱导鼻咽癌的癌症干细胞样特性和治疗耐药性。
DOI:
10.1158/1078-0432.ccr-17-0352
发表时间:
2018-02-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
[Zhong Q, Liu ZH, Lin ZR, Hu ZD, Yuan L, Liu YM, Zhou AJ, Xu LH, Hu LJ, Wang ZF, Guan XY, Hao JJ, Lui VWY, Guo L, Mai HQ, Chen MY, Han F, Xia YF, Grandis JR, Zhang X, Zeng MS]
通讯作者:
Zeng MS
ALG3 contributes to stemness and radioresistance through regulating glycosylation of TGF-β receptor II in breast cancer.
ALG3 通过调节乳腺癌中 TGF-β 受体 II 的糖基化有助于干性和放射抗性
DOI:
10.1186/s13046-021-01932-8
发表时间:
2021-04-30
期刊:
Journal of experimental & clinical cancer research : CR
影响因子:
--
作者:
[Sun X, He Z, Guo L, Wang C, Lin C, Ye L, Wang X, Li Y, Yang M, Liu S, Hua X, Wen W, Lin C, Long Z, Zhang W, Li H, Jian Y, Zhu Z, Wu X, Lin H]
通讯作者:
Lin H
Sarcopenia is associated with higher toxicity and poor prognosis of nasopharyngeal carcinoma
肌肉减少症与鼻咽癌的较高毒性和不良预后相关
DOI:
10.1177/1758835920947612
发表时间:
2020-08-01
期刊:
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
影响因子:
4.9
作者:
[Hua, Xin, Liao, Jun-Fang, Lin, Huan-Xin]
通讯作者:
Lin, Huan-Xin
IQGAP3 Overexpression Correlates With Poor Prognosis and Radiation Therapy Resistance in Breast Cancer.
IQGAP3 过度表达与乳腺癌不良预后和放射治疗耐药性相关
DOI:
10.3389/fphar.2020.584450
发表时间:
2020
期刊:
Frontiers in pharmacology
影响因子:
5.6
作者:
[Hua X, Long ZQ, Guo L, Wen W, Huang X, Zhang WW]
通讯作者:
Zhang WW
共 21 条
GATA6促进鼻咽癌放疗抵抗的分子机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:郭灵
-
依托单位:
TBLR1诱导鼻咽癌转移的分子机制
-
批准号:81572848
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:郭灵
-
依托单位:
国内基金
海外基金